Published in Hum Pathol on October 21, 2013
The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis (2017) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature (2009) 4.83
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol (2009) 2.30
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem (2005) 2.05
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res (2005) 1.94
Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol (2013) 1.82
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
Histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications. J Urol (2003) 1.68
Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol (2010) 1.65
Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol (2004) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res (2003) 1.55
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
B7-H4 overexpression in ovarian tumors. Gynecol Oncol (2005) 1.51
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med (2008) 1.33
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol (2008) 1.32
Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int (2005) 1.32
Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer (2007) 1.30
B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol (2007) 1.25
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology (2007) 1.24
Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med (2007) 1.23
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol (2005) 1.20
Staging of prostate cancer. Histopathology (2012) 1.19
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate (2012) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
High-grade prostatic intraepithelial neoplasia. Rev Urol (2004) 1.18
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int (2005) 1.17
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol (2012) 1.16
Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol (2006) 1.15
Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol (2007) 1.13
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol (2011) 1.11
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res (2007) 1.11
Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int (2005) 1.10
Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology (2007) 1.09
Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am J Surg Pathol (2003) 1.08
Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer (2002) 1.07
Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology (2011) 1.06
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res (2013) 1.06
Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas (2008) 1.05
Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology (2007) 1.05
Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis (2005) 1.04
Needle core length in sextant biopsy influences prostate cancer detection rate. Urology (2002) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol (2007) 1.03
Prostate biopsy and optimization of cancer yield. Eur Urol (2006) 1.02
Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst (2005) 1.02
Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose Response (2009) 1.02
2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res (2006) 1.02
Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol (2005) 1.01
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol (2003) 1.00
Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol (2004) 0.99
Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res (2009) 0.99
Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol (2012) 0.99
Tubulocystic carcinoma, mucinous tubular and spindle cell carcinoma, and other recently described rare renal tumors. Clin Lab Med (2005) 0.98
Gadolinium-enhanced MRI in the evaluation of minimally invasive treatments of the prostate: correlation with histopathologic findings. Urology (2003) 0.98
Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prev Res (Phila) (2010) 0.98
Prostatic leiomyoma with atypia: follow-up study of 10 cases. Ann Diagn Pathol (2008) 0.97
Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep (2011) 0.97
Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol (2006) 0.97